glp-1 prescriptions growth slowing 2024 Agonists Weight Loss Drugs Market Report, 2025-2030 New Demand in an Old
Description
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Because of GLP-1 agonists may not be appropriate or desired for everyone
PlexusDx does not sell, prescribe, or recommend any other therapeutic peptide in the GLP-1 category beyond semaglutide and tirzepatide (including dulaglutide, liraglutide, retatrutide, cagrilintide, and related compounds)
Many telehealth companies dont proactively monitor their patients for side effects or to adjust their medication dosage
